Our Events

Intraoperative hypotension remains closely linked to adverse outcomes, yet whether treating it improves those outcomes continues to be debated. Join Dr. Joseph Antognini, Chief Scientific Officer of Expanesthetics, as we examine the evidence linking intraoperative hypotension to adverse outcomes and the tradeoffs inherent in today's anesthetic choices. We will examine how commonly used agents contribute to hypotension, the clinical burden of managing its downstream effects, and the emerging science that challenges long-held assumptions. We will end by examining how future anesthetics may fundamentally alter the hemodynamic profiles we currently accept as unavoidable.

Inhaled anesthetics remain essential to modern surgery, yet the discovery of new agents has been stalled for decades. In this session, Dr. Shane Austin, CEO of Expanesthetics, will explain why pursuing new inhaled anesthetics still matters and why it has proven so difficult. A significant discovery around the molecular mechanism of action of the volatile anesthetics offers an efficient path toward identifying new agents. Recent findings from Expanesthetics' pre-clinical research reveal several compounds with blood-pressure sparing effects, suggesting that smart design could shape the next generation of inhaled anesthesia.